These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 24759597

  • 1. SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.
    Bu Q, Cui L, Li J, Du X, Zou W, Ding K, Pan J.
    Cancer Biol Ther; 2014 Jul; 15(7):951-62. PubMed ID: 24759597
    [Abstract] [Full Text] [Related]

  • 2. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 3. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
    Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K.
    Blood; 2003 Apr 15; 101(8):3236-9. PubMed ID: 12446442
    [Abstract] [Full Text] [Related]

  • 4. Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.
    Gupta P, Zhang GN, Barbuti AM, Zhang X, Karadkhelkar N, Zhou J, Ding K, Pan J, Yoganathan S, Yang DH, Chen ZS.
    Cancer Lett; 2020 Mar 01; 472():132-141. PubMed ID: 31837444
    [Abstract] [Full Text] [Related]

  • 5. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
    Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S.
    Blood; 2003 Nov 15; 102(10):3765-74. PubMed ID: 12893773
    [Abstract] [Full Text] [Related]

  • 6. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B, Wang Q, Liu X, Lu Z, Han J, Pan C, Carter BZ, Liu Q, Xu N, Zhou H.
    Biomed Pharmacother; 2020 Sep 15; 129():110390. PubMed ID: 32563150
    [Abstract] [Full Text] [Related]

  • 7. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
    Lu Z, Jin Y, Chen C, Li J, Cao Q, Pan J.
    Mol Cancer; 2010 May 19; 9():112. PubMed ID: 20482842
    [Abstract] [Full Text] [Related]

  • 8. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
    Shi X, Chen X, Li X, Lan X, Zhao C, Liu S, Huang H, Liu N, Liao S, Song W, Zhou P, Wang S, Xu L, Wang X, Dou QP, Liu J.
    Clin Cancer Res; 2014 Jan 01; 20(1):151-63. PubMed ID: 24334603
    [Abstract] [Full Text] [Related]

  • 9. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.
    Dai Y, Chen S, Venditti CA, Pei XY, Nguyen TK, Dent P, Grant S.
    Blood; 2008 Aug 01; 112(3):793-804. PubMed ID: 18505786
    [Abstract] [Full Text] [Related]

  • 10. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
    Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.
    Blood; 2008 Apr 15; 111(8):4355-64. PubMed ID: 18268096
    [Abstract] [Full Text] [Related]

  • 11. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
    Dasmahapatra G, Patel H, Nguyen T, Attkisson E, Grant S.
    Clin Cancer Res; 2013 Jan 15; 19(2):404-14. PubMed ID: 23204129
    [Abstract] [Full Text] [Related]

  • 12. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
    Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M, Grant S.
    Clin Cancer Res; 2011 May 15; 17(10):3219-32. PubMed ID: 21474579
    [Abstract] [Full Text] [Related]

  • 13. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM, Jung KH, Kim SJ, Fang Z, Son MK, Yan HH, Lee H, Kim J, Shin S, Hong S, Hong SS.
    Cancer Lett; 2014 Jun 28; 348(1-2):50-60. PubMed ID: 24657654
    [Abstract] [Full Text] [Related]

  • 14. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, Calin GA, Ivan C, Covas DT, Kashima S, Castro FA.
    Blood Cells Mol Dis; 2014 Jun 28; 53(1-2):47-55. PubMed ID: 24629639
    [Abstract] [Full Text] [Related]

  • 15. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX, Wu Y, Chen RJ, Liu Y, Huang LS, Lou LG, Zheng ZH, Chen YZ, Xu JH.
    Acta Pharmacol Sin; 2014 Mar 28; 35(3):401-9. PubMed ID: 24487968
    [Abstract] [Full Text] [Related]

  • 16. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.
    Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S, Rocha K, Wu J, Giles F, Manley PW, Atadja P, Bhalla K.
    Blood; 2006 Jul 15; 108(2):645-52. PubMed ID: 16537804
    [Abstract] [Full Text] [Related]

  • 17. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
    Borgo C, Cesaro L, Salizzato V, Ruzzene M, Massimino ML, Pinna LA, Donella-Deana A.
    Mol Oncol; 2013 Dec 15; 7(6):1103-15. PubMed ID: 24012109
    [Abstract] [Full Text] [Related]

  • 18. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
    Cassuto O, Dufies M, Jacquel A, Robert G, Ginet C, Dubois A, Hamouda A, Puissant A, Luciano F, Karsenti JM, Legros L, Cassuto JP, Lenain P, Auberger P.
    Oncotarget; 2012 Dec 15; 3(12):1557-65. PubMed ID: 23238683
    [Abstract] [Full Text] [Related]

  • 19. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K, Mahon FX, Josselin M, Jeanneteau M, Turcq B, Belloc F.
    Exp Hematol; 2012 May 15; 40(5):367-78.e2. PubMed ID: 22240609
    [Abstract] [Full Text] [Related]

  • 20. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
    Matsuda Y, Yamauchi T, Hosono N, Uzui K, Negoro E, Morinaga K, Nishi R, Yoshida A, Kimura S, Maekawa T, Ueda T.
    Cancer Sci; 2016 Jul 15; 107(7):1029-38. PubMed ID: 27166836
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.